ReShape Lifesciences Inc (RSLS) News

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

Revenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential...

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier...

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes B

IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier...

Form 8-K - Current report

Form S-4 - Registration of securities, business combinations

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update

Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys...